Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
Information source: The Hospital for Sick Children
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hemophilia A
Intervention: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: The Hospital for Sick Children Official(s) and/or principal investigator(s):
Brian Feldman, MD, Principal Investigator, Affiliation: The Hospital for Sick Children
Overall contact:
Brian Feldman, MD, Phone: (416)813-5677, Email: brian.feldman@sickkids.ca
Summary
The primary objective of this study is to test the feasibility of a large-scale clinical
trial of once-daily prophylaxis. The secondary objectives are to collect clinical efficacy
outcomes so that we can better plan a large-scale study; we will estimate the effect size and
variability of effect and resource utilization of once-daily prophylaxis to allow us to set a
sample size for a definitive trial.
Clinical Details
Official title: Pilot Study of Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
Study design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study
Primary outcome: To test the feasibility of a large-scale clinical trial of once-daily prophylaxis. As such, the primary outcome will be related to process measures.
Secondary outcome: Clinical efficacyEstimate the effect size and variability of effect and resource utilization of once-daily prophylaxis.
Detailed description:
Hemophilia is an important and costly disorder; if left untreated, it may have serious
consequences. The greatest impact of hemophilia occurs from recurrent bleeding into joints.
The consequences of joint bleeding include pain associated with acute bleeding and later
chronic arthropathy. Half of affected children with severe hemophilia have joint damage;
joint damage is more frequent with increased bleeding. The prevention and treatment of
bleeding is very expensive and therefore finding a cost-effective treatment is of high
priority.
Worldwide, two major treatment strategies have been used to prevent arthropathy - on demand
therapy and factor prophylaxis. The goal of prophylaxis is to convert the severe to the
moderate phenotype by providing circulating factor activity of greater than 1%. Patients
with greater than 1% circulating factor VIII activity rarely have spontaneous hemarthroses.
Therefore, the goal of providing circulating factor at this level is to eliminate spontaneous
hemarthroses. The term primary prophylaxis suggests using preventative factor VIII
replacement from a very early age. The term secondary prophylaxis is used to describe the
application of prophylaxis at a later disease stage. In this study, secondary prophylaxis
will be used.
Once-daily prophylaxis is a novel application of hemophilia factor prophylaxis for youth and
young adults. Before embarking on a costly definitive trial we feel that it is necessary to
demonstrate that subjects will be willing to enroll and will be compliant with the therapy.
Moreover, we need to establish an estimate of the effect of once-daily prophylaxis on
bleeding rates, quality of life, and joint damage progression in order to design a definitive
trial.
Eligibility
Minimum age: 12 Years.
Maximum age: 24 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Severe hemophilia A (<1% factor VIII)
- Age 12 to 24 years inclusive
- Male
- No current factor VIII inhibitor (an inhibitor will be defined as ≥ 0. 6 Bethesda
Units) within the past year
- Able to participate in a home infusion program with adequate peripheral venous access
as assessed ny the treating investigator
Exclusion Criteria:
- Important co-morbidities (Acquired Immunodeficiency Syndrome or symptomatic HIV
infection, symptomatic hepatitis B or C infection)
- Other concomitant acquired or congenital bleeding disorder (e. g. von Willebrand's
Disease)
- Receiving factor VIII replacement through central venous catheter
Locations and Contacts
Brian Feldman, MD, Phone: (416)813-5677, Email: brian.feldman@sickkids.ca
The Hospital for Sick Children, Toronto, Ontario, Canada; Recruiting
Brian Feldman, Phone: (416)813-5677, Email: brian.feldman@sickkids.ca
St. Michael's Hospital, Toronto, Ontario, Canada; Recruiting
Jerome Teitel
Hospital Sainte-Justine, Montreal, Quebec, Canada; Recruiting
Georges Rivard
Additional Information
Starting date: July 2008
Ending date: December 2009
Last updated: September 19, 2008
|
